Jason Luke Joins physIQ’s Medical Advisory Board

physIQ has appointed Jason Luke, M.D., FACP, to the company’s Medical Advisory Board. In this role, Luke will provide expert medical counsel for physIQ’s ongoing development of solutions to aide in oncology treatments, including physIQ’s development of digital biomarkers for inflammation.
 
“Dr. Luke brings extensive immuno-oncology expertise to physIQ that will provide immeasurable insight into our work on inflammation and oncology treatments,” physIQ Chief Medical Officer Steve Steinhubl, M.D., said. “As a practicing physician and researcher, he brings the vision, experience, and empathy that we embrace at physIQ.”
 
One of Luke’s first projects with physIQ is to serve as principal investigator on a clinical study designed to show how the company’s Inflammatory Multivariate Change Index (iMCI) can make CAR-T, a ground-breaking oncology treatment, safer and more accessible by enabling real-time in-home safety monitoring post CAR-T dosing. Luke is director of the Immunotherapy and Drug Development Center at the University of Pittsburgh Medical Center Hillman Cancer Center and associate professor at the University of Pittsburgh. He focuses on translational therapeutic advances in immuno-oncology, early phase drug development for advanced solid tumors and the management of patients with cutaneous malignancies.
 
In melanoma, Luke has designed and led two practice-changing studies documenting the role of combination anti-PD1 + low dose anti-CTLA4 Ab in PD1 refractory disease, as well as establishing the role for, and U.S. Food and Drug Administration/EMA approval of, adjuvant anti-PD1 for stage IIB/C melanoma. More generally, Luke has been a lead investigator for clinical trials of many novel immunotherapies in advanced solid tumors. He has been a major contributor toward the investigation of radiation and the microbiome in relation to cancer immunotherapy.
 
Luke’s translational research laboratory focuses on biomedical and bioinformatic approaches to advance cancer immunotherapy. He is an at-large member of the Society for Immunotherapy of Cancer Board of Directors and has held leadership roles in SMR, American Association for Cancer Rresearch, and American Society of Clinical Oncology. Luke is the PI or project leader for multiple funding mechanisms including R01, UM1, P50 and multiple state or private grants.
 
Luke earned his medical degree from Rosalind Franklin University of Medicine and Science/Chicago Medical School in North Chicago. He completed an internship and residency in internal medicine at Boston University Medical Center and fellowships in medicine and medical oncology at Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York City.
 
physIQ delivers personalized medical predictions that vastly improve patient outcomes. By combining proprietary AI and any wearable biosensor to continuously monitor patients in real-world settings, physIQ advances medicine and enables clinical trial sponsors and clinicians to proactively detect physiological decompensations, improve the safety and efficacy of new therapies and speed time to market, and deliver personalized clinical interventions to improve patient outcomes.